Table 3. Incidence of adverse events recorded in 1,210 pediatric patients treated with meglumine antimoniate.
Parameter | Frequency (%) |
Decrease of hemoglobin | 20 |
Hyperamylasemia | 10 |
Hypokalemia | 7 |
ECG modifications | 6 |
Hyponatremia | 2 |
Nefrotoxicity | 2 |
Liver enzyme (ALT) increase | 1 |